GILEAD SCIENCES, INC. Derivative Asset, Fair Value, Gross Asset
GILEAD SCIENCES, INC. (GILD) had Derivative Asset, Fair Value, Gross Asset of $80.00 million as of 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Notes › Offsetting › Offsetting Derivative Assets › Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral
us-gaap:DerivativeFairValueOfDerivativeAsset · last filed 2022-02-23
- 2021-12-31: Derivative Asset, Fair Value, Gross Asset $80.00M.
- 2021-09-30: Derivative Asset, Fair Value, Gross Asset $55.00M.
- 2021-06-30: Derivative Asset, Fair Value, Gross Asset $28.00M.
- 2021-03-31: Derivative Asset, Fair Value, Gross Asset $32.00M.
| Period end | Derivative Asset, Fair Value, Gross Asset | Derivative Asset, Fair Value, Gross Asset as first filed |
|---|---|---|
| 2021-12-31 | $80.00M 10-K · filed 2022-02-23 | |
| 2021-09-30 | $55.00M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $28.00M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $32.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $12.00M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $6.00M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $21.00M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $76.00M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $37.00M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $80.00M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $48.00M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $77.00M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $78.00M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $42.00M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $53.00M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $4.00M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $13.00M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $30.00M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $51.00M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $167.00M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $336.00M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $65.00M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $91.00M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $74.00M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $210.00M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $267.00M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $342.00M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $607.00M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $349.00M 10-K · filed 2016-02-24 | |
| 2014-09-30 | $215.91M 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $22.87M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $11.03M 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $14.00M 10-K · filed 2015-02-25 | $13.88M 10-K · filed 2014-02-25 |
| 2013-09-30 | $8.98M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $41.43M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $43.18M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $14.82M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $57.30M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $134.46M 10-Q · filed 2012-08-01 | |
| 2012-03-31 | $51.96M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $100.47M 10-K · filed 2013-02-27 | |
| 2011-09-30 | $46.23M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $2.21M 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $8.02M 10-Q · filed 2011-05-09 | |
| 2010-12-31 | $64.46M 10-K · filed 2012-02-23 | |
| 2010-09-30 | $51.87M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $203.35M 10-Q · filed 2010-08-09 | |
| 2009-12-31 | $26.20M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |